Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Pathways

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:D-galactosamine
go back to main search page
Accession:CHEBI:28328 term browser browse the term
Definition:The D-stereoisomer of galactosamine.
Synonyms:related_synonym: Formula=C6H13NO5
 alt_id: CHEBI:20951;   CHEBI:4135;   CHEBI:447526
 xref: PMID:16530410;   PMID:19067146;   PMID:6196640;   Wikipedia:Galactosamine



show annotations for term's descendants           Sort by:
2-amino-2-deoxy-D-galactopyranose term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ache acetylcholinesterase increases activity
multiple interactions
EXP Galactosamine results in increased activity of ACHE protein
Vitamin U inhibits the reaction [Galactosamine results in increased activity of ACHE protein]
CTD PMID:35673974 NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410
JBrowse link
G Acta2 actin alpha 2, smooth muscle increases expression
multiple interactions
EXP Galactosamine results in increased expression of ACTA2 mRNA; Galactosamine results in increased expression of ACTA2 protein
Genistein inhibits the reaction [Galactosamine results in increased expression of ACTA2 mRNA]; Genistein inhibits the reaction [Galactosamine results in increased expression of ACTA2 protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of ACTA2 protein]
CTD PMID:27836788 PMID:27876602 NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
JBrowse link
G Actb actin, beta increases expression EXP Galactosamine results in increased expression of ACTB mRNA CTD PMID:22563491 NCBI chr12:16,776,664...16,779,634
Ensembl chr12:16,776,661...16,780,242
JBrowse link
G Afp alpha-fetoprotein increases expression EXP Galactosamine results in increased expression of AFP protein CTD PMID:61145 PMID:16965562 NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,857,584...17,875,649
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of AKT1 protein]]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of AKT1 protein; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of AKT1 protein] CTD PMID:37934488 NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
JBrowse link
G Alb albumin multiple interactions
increases expression
decreases expression
EXP [ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of IL10 protein; [ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased expression of ALB protein; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased expression of ALB protein]
Galactosamine results in increased expression of ALB mRNA
Galactosamine results in decreased expression of ALB protein
CTD PMID:17963606 PMID:18779383 PMID:22310181 PMID:35838105 NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865
JBrowse link
G Ambp alpha-1-microglobulin/bikunin precursor increases expression EXP Galactosamine results in increased expression of AMBP mRNA CTD PMID:18779383 NCBI chr 5:76,568,094...76,578,416
Ensembl chr 5:81,583,622...81,593,850
JBrowse link
G Apoe apolipoprotein E decreases expression EXP Galactosamine results in decreased expression of APOE protein CTD PMID:6631239 NCBI chr 1:88,481,889...88,485,816
Ensembl chr 1:88,481,385...88,485,855
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions EXP 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 protein CTD PMID:28844859 NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739
JBrowse link
G Atm ATM serine/threonine kinase increases expression
multiple interactions
EXP Galactosamine results in increased expression of ATM protein
glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of ATM protein]
CTD PMID:24565947 NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:62,727,291...62,828,629
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
ISO
EXP
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of BAX protein]]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BAX protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form]; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BAX protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form]
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX mRNA; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of BAX mRNA]
Galactosamine results in increased expression of BAX mRNA; Galactosamine results in increased expression of BAX protein
CTD PMID:20558151 PMID:20850421 PMID:21401295 PMID:22118634 PMID:24565947 More... NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression
ISO
EXP
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of BCL2 protein]]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BCL2 protein; [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form]; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BCL2 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form]
Galactosamine results in decreased expression of BCL2 mRNA; Galactosamine results in decreased expression of BCL2 protein
glycine propionyl carnitine inhibits the reaction [Galactosamine results in decreased expression of BCL2 mRNA]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of BCL2 protein]
CTD PMID:20558151 PMID:20850421 PMID:22118634 PMID:24565947 PMID:37934488 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BID mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of BID protein CTD PMID:12907702 PMID:21401295 NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:155,785,377...155,808,275
JBrowse link
G Casp1 caspase 1 multiple interactions ISO [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP1 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP1 protein] CTD PMID:32453893 NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275
JBrowse link
G Casp3 caspase 3 multiple interactions
increases activity
increases expression
ISO
EXP
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of CASP3 protein]]; 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP3 protein]; [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein; [Galactosamine co-treated with Endotoxins] results in increased activity of CASP3 protein; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of CASP3 protein; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein]; Biliverdine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]]; Dithiothreitol inhibits the reaction [Nitric Oxide Donors inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]]; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of CASP3 protein]; gentiopicroside inhibits the reaction [[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form]; Melatonin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein]; Methylene Chloride inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP3 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein]
2-Acetylaminofluorene inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of CASP3 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of CASP3 protein; Alprostadil inhibits the reaction [Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein]; Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of CASP3 mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of CASP3 protein]
Galactosamine results in increased expression of CASP3 mRNA; Galactosamine results in increased expression of CASP3 protein
[Galactosamine co-treated with TNF protein] results in increased activity of CASP3 protein; alpha-Tocopherol inhibits the reaction [Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein]; Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein; Ketoconazole inhibits the reaction [Galactosamine results in increased activity of CASP3 protein]; Rifampin promotes the reaction [Galactosamine results in increased activity of CASP3 protein]
CTD PMID:9388267 PMID:12907702 PMID:14512878 PMID:15486963 PMID:15565661 More... NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
JBrowse link
G Casp7 caspase 7 multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP7 protein; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP7 protein] CTD PMID:21146893 NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512
JBrowse link
G Casp8 caspase 8 multiple interactions ISO 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP8 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP8 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP8 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP8 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP8 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP8 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP8 protein modified form]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP8 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP8 protein] CTD PMID:20558151 PMID:20850421 PMID:21146893 PMID:24830863 PMID:31332890 NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
JBrowse link
G Casp9 caspase 9 multiple interactions
increases expression
ISO
EXP
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP9 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP9 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP9 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP9 protein; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP9 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP9 protein modified form]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP9 protein]
Galactosamine results in increased expression of CASP9 protein
mangiferin inhibits the reaction [Galactosamine results in increased expression of CASP9 protein]
CTD PMID:20558151 PMID:22118634 PMID:24830863 PMID:31332890 Ensembl chr 5:159,391,188...159,409,648 JBrowse link
G Cat catalase multiple interactions
decreases activity
increases activity
ISO
EXP
6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased activity of CAT protein]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; [Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased activity of CAT protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Caffeine inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Oligopeptides inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]]
[Ascorbic Acid co-treated with beta Carotene co-treated with alpha-Tocopherol co-treated with Sodium Selenite] inhibits the reaction [Galactosamine results in increased activity of CAT protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of CAT protein; glycine propionyl carnitine inhibits the reaction [Galactosamine results in decreased activity of CAT protein]; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of CAT protein]; Vitamin U inhibits the reaction [Galactosamine results in decreased activity of CAT protein]
CTD PMID:19153979 PMID:22154906 PMID:27836788 PMID:30236599 PMID:31022331 More... NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO 1-hydroxyalantolactone inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased expression of CCL2 mRNA]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CCL2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein; [TNF protein co-treated with Galactosamine] results in increased expression of CCL2 mRNA; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CCL2 mRNA]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]] CTD PMID:21146893 PMID:25200604 PMID:28887131 PMID:35691465 NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein] CTD PMID:21146893 NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein; Indomethacin promotes the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein]; nimesulide promotes the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein] CTD PMID:22107987 NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein; baicalein inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein]; Silymarin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein] CTD PMID:20850421 NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434
JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex increases phosphorylation
multiple interactions
EXP Galactosamine results in increased phosphorylation of CHUK protein
mangiferin inhibits the reaction [Galactosamine results in increased phosphorylation of CHUK protein]
CTD PMID:22310181 NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:252,908,749...252,944,273
JBrowse link
G Col1a1 collagen type I alpha 1 chain increases expression
multiple interactions
EXP Galactosamine results in increased expression of COL1A1 mRNA
Genistein inhibits the reaction [Galactosamine results in increased expression of COL1A1 mRNA]
CTD PMID:27876602 NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460
JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions
increases expression
EXP Genistein inhibits the reaction [Galactosamine results in increased expression of COL3A1 mRNA] CTD PMID:27876602 NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:54,866,632...54,903,232
JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A multiple interactions
decreases expression
ISO alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of CPT1A mRNA] CTD PMID:17936189 NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326
JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL2 mRNA; [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL2 protein CTD PMID:15576625 NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255
JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions ISO [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL1 mRNA; [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL1 protein CTD PMID:15576625 NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624
JBrowse link
G Cyba cytochrome b-245 alpha chain multiple interactions ISO [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CYBA protein; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CYBA protein] CTD PMID:28887131 NCBI chr19:67,396,143...67,404,214
Ensembl chr19:67,396,143...67,404,214
JBrowse link
G Cycs cytochrome c, somatic multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in increased localization of CYCS protein; [Lipopolysaccharides co-treated with Galactosamine] affects the localization of CYCS protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of CYCS protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased localization of CYCS protein] CTD PMID:20558151 PMID:20850421 NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 decreases expression EXP Galactosamine results in decreased expression of CYP1A2 protein CTD PMID:16208626 NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 decreases expression
multiple interactions
EXP Galactosamine results in decreased expression of CYP2E1 protein
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of CYP2E1 protein; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of CYP2E1 protein]
CTD PMID:16208626 PMID:35838105 NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 decreases expression
multiple interactions
ISO Galactosamine results in decreased expression of CYP3A4 mRNA
alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [alpha-Tocopherol results in increased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]
CTD PMID:17936189 NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions EXP 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of DDIT3 mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of DDIT3 mRNA CTD PMID:28844859 NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509
JBrowse link
G Egfr epidermal growth factor receptor multiple interactions EXP [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR mRNA; [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR protein; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR mRNA]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR protein] CTD PMID:36414212 NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions EXP 4-phenylbutyric acid affects the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased phosphorylation of EIF2S1 protein]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of EIF2S1 mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of and results in decreased phosphorylation of EIF2S1 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of EIF2S1 mRNA CTD PMID:28844859 NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:103,405,788...103,431,649
JBrowse link
G G6pd glucose-6-phosphate dehydrogenase multiple interactions EXP [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of G6PD protein; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of G6PD protein] CTD PMID:35838105 NCBI chr  X:157,352,364...157,372,144
Ensembl chr  X:157,352,373...157,372,144
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions ISO 8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLC mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLC mRNA; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLC mRNA] CTD PMID:35691465 NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893
JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions ISO 8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLM mRNA]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GCLM mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLM mRNA; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLM mRNA] CTD PMID:28887131 PMID:35691465 NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003
JBrowse link
G Gdf11 growth differentiation factor 11 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of BAX protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of MTOR protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of PIK3R1 protein]]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GDF11 protein; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of CASP3 protein]; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BAX protein]; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BCL2 protein]; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of AKT1 protein]; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of MTOR protein]; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of PIK3R1 protein] CTD PMID:37934488 NCBI chr 7:1,896,229...1,909,147
Ensembl chr 7:1,896,229...1,905,222
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions
increases expression
EXP
ISO
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein; [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of GPT protein; Genistein inhibits the reaction [Galactosamine results in increased expression of GPT protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of GPT protein]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of GPT protein]; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of GPT protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of GPT protein]
(2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]]; (2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]]; 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]; 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein; [Galactosamine co-treated with Lipopolysaccharides] promotes the reaction [idelalisib results in increased expression of ALT protein]; [Galactosamine co-treated with Lipopolysaccharides] promotes the reaction [Miransertib results in increased expression of ALT protein]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of GPT protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein; Acetylcysteine inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of GPT protein]; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; Plant Extracts inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of GPT protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein]; stattic inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]
CTD PMID:19153979 PMID:24565947 PMID:24830863 PMID:25620059 PMID:27876602 More... NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions
decreases activity
EXP [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of GSR protein; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of GSR protein]; Vitamin U inhibits the reaction [Galactosamine results in decreased activity of GSR protein] CTD PMID:35673974 PMID:35838105 NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394
JBrowse link
G Gstt3 glutathione S-transferase, theta 3 affects response to substance EXP GSTT3 mRNA affects the susceptibility to Galactosamine CTD PMID:19800905 NCBI chr20:12,873,618...12,881,974
Ensembl chr20:12,874,374...12,881,973
JBrowse link
G H3f4 H3.4 histone, cluster member increases expression EXP Galactosamine results in increased expression of H3F4 mRNA CTD PMID:11779202 NCBI chr10:44,240,282...44,240,842 JBrowse link
G Habp2 hyaluronan binding protein 2 increases activity ISO Galactosamine results in increased activity of HABP2 protein CTD PMID:11510480 NCBI chr 1:265,321,084...265,355,375
Ensembl chr 1:265,303,172...265,355,374
JBrowse link
G Hbegf heparin-binding EGF-like growth factor multiple interactions ISO [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA] CTD PMID:28887131 NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,380,337...28,390,220
JBrowse link
G Hgf hepatocyte growth factor multiple interactions EXP 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF protein]; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF protein CTD PMID:28844859 NCBI chr 4:19,628,902...19,700,467
Ensembl chr 4:19,632,267...19,700,851
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
decreases expression
ISO
EXP
8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]; 8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein; Galactosamine inhibits the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]]
[[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HMOX1 mRNA] which results in increased chemical synthesis of Bilirubin; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HMOX1 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of HMOX1 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA; mangiferin inhibits the reaction [Galactosamine results in decreased expression of HMOX1 protein]; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of HMOX1 protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]
CTD PMID:14512878 PMID:19796704 PMID:21401295 PMID:22310181 PMID:35691465 More... NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
JBrowse link
G Hp haptoglobin multiple interactions EXP [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HP protein; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HP protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HP protein] CTD PMID:36414212 NCBI chr19:54,449,151...54,453,701
Ensembl chr19:54,446,217...54,467,518
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions EXP 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 protein CTD PMID:28844859 NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO Galactosamine analog inhibits the reaction [TNF results in increased expression of ICAM1 protein]
1-hydroxyalantolactone inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased expression of ICAM1 mRNA]; [TNF protein co-treated with Galactosamine] results in increased expression of ICAM1 mRNA
CTD PMID:16431966 PMID:25200604 NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
JBrowse link
G Ifng interferon gamma multiple interactions
increases expression
ISO
EXP
[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG mRNA]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein]
Galactosamine results in increased expression of IFNG mRNA
mangiferin inhibits the reaction [Galactosamine results in increased expression of IFNG mRNA]
CTD PMID:15486963 PMID:22310181 NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 increases expression EXP Galactosamine results in increased expression of IGFBP1 mRNA CTD PMID:11779202 NCBI chr14:86,261,277...86,266,344
Ensembl chr14:86,261,277...86,266,344
JBrowse link
G Ikbkb inhibitor of nuclear factor kappa B kinase subunit beta multiple interactions
increases phosphorylation
EXP mangiferin inhibits the reaction [Galactosamine results in increased phosphorylation of IKBKB protein] CTD PMID:22310181 NCBI chr16:76,021,968...76,075,717
Ensembl chr16:76,022,008...76,081,911
JBrowse link
G Il10 interleukin 10 multiple interactions
decreases expression
ISO
EXP
[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein]
[ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of IL10 protein; mangiferin inhibits the reaction [Galactosamine results in decreased expression of IL10 mRNA]
CTD PMID:15486963 PMID:17963606 PMID:22310181 NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
JBrowse link
G Il12b interleukin 12B multiple interactions
increases expression
ISO
EXP
[LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA
Galactosamine results in increased expression of IL12B mRNA
mangiferin inhibits the reaction [Galactosamine results in increased expression of IL12B mRNA]
CTD PMID:19913045 PMID:22310181 NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194
JBrowse link
G Il18 interleukin 18 increases expression
multiple interactions
ISO
EXP
Galactosamine results in increased expression of IL18 mRNA; Galactosamine results in increased expression of IL18 protein
[LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; Plant Preparations inhibits the reaction [Galactosamine results in increased expression of IL18 mRNA]; Plant Preparations inhibits the reaction [Galactosamine results in increased expression of IL18 protein]
mangiferin inhibits the reaction [Galactosamine results in increased expression of IL18 mRNA]
CTD PMID:19913045 PMID:20102673 PMID:22310181 NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286
JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression
EXP
ISO
Genistein inhibits the reaction [Galactosamine results in increased expression of IL1B mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of IL1B mRNA]
2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein]]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; nilotinib inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL1B protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]]
CTD PMID:15135310 PMID:22310181 PMID:25620059 PMID:28125915 PMID:28887131 More... NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression
ISO
EXP
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]]
[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of IL6 protein; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of IL6 mRNA]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of IL6 protein]; mangiferin inhibits the reaction [Galactosamine results in increased expression of IL6 mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of IL6 protein]
CTD PMID:15135310 PMID:15486963 PMID:22310181 PMID:24830863 PMID:27836788 More... NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
JBrowse link
G Irak1 interleukin-1 receptor-associated kinase 1 multiple interactions ISO [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of IRAK1 protein; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]] CTD PMID:28213090 NCBI chr  X:156,919,927...156,929,825
Ensembl chr  X:156,920,081...156,929,825
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 multiple interactions ISO 8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased degradation of KEAP1 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased degradation of KEAP1 protein; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased degradation of KEAP1 protein]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased degradation of KEAP1 protein] CTD PMID:35691465 NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042
JBrowse link
G Lcat lecithin cholesterol acyltransferase decreases activity EXP Galactosamine results in decreased activity of LCAT protein CTD PMID:6631239 NCBI chr19:50,744,598...50,748,064
Ensembl chr19:50,744,601...50,748,081
JBrowse link
G Lep leptin multiple interactions
increases response to substance
ISO [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEP gene mutant form results in increased susceptibility to Galactosamine] CTD PMID:19913045 NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661
JBrowse link
G Lepr leptin receptor multiple interactions
increases response to substance
ISO [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEPR gene mutant form results in increased susceptibility to Galactosamine] CTD PMID:19913045 NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:121,474,099...121,591,215
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation
ISO
EXP
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased phosphorylation of MAPK1 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK1 protein modified form; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK1 protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form]
Galactosamine results in increased phosphorylation of MAPK1 protein
Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of MAPK1 protein]
CTD PMID:20558151 PMID:20850421 PMID:25620059 PMID:28887131 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
ISO
EXP
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased phosphorylation of MAPK3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK3 protein modified form; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK3 protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form]
Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of MAPK3 protein]
CTD PMID:20558151 PMID:20850421 PMID:25620059 PMID:28887131 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
JBrowse link
G Maz MYC associated zinc finger protein multiple interactions EXP [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ mRNA; [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ protein; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ mRNA]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ protein] CTD PMID:36414212 NCBI chr 1:181,629,742...181,635,193
Ensembl chr 1:191,060,280...191,065,339
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions EXP
ISO
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of MET mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of MET mRNA
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of MET mRNA
CTD PMID:28844859 PMID:28887131 NCBI chr 4:46,756,823...46,864,041
Ensembl chr 4:46,756,506...46,870,821
JBrowse link
G Mgst1 microsomal glutathione S-transferase 1 multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of MGST1 protein; Dithiothreitol inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of MGST1 protein] CTD PMID:18634816 NCBI chr 4:172,760,930...172,776,157
Ensembl chr 4:172,760,886...172,776,875
JBrowse link
G Mir34c microRNA 34c multiple interactions EXP [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MIR34C mRNA; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MIR34C mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MIR34C mRNA] CTD PMID:36414212 NCBI chr 8:60,306,091...60,306,167 JBrowse link
G Mpo myeloperoxidase multiple interactions
increases activity
ISO
EXP
(2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein]]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of MPO protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of MPO protein]
[Ascorbic Acid co-treated with beta Carotene co-treated with alpha-Tocopherol co-treated with Sodium Selenite] inhibits the reaction [Galactosamine results in increased activity of MPO protein]; Vitamin U inhibits the reaction [Galactosamine results in increased activity of MPO protein]
CTD PMID:28887131 PMID:30550845 PMID:31022331 PMID:32453893 PMID:35673974 NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of MTOR protein]]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of MTOR protein; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of MTOR protein] CTD PMID:37934488 NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435
JBrowse link
G Ndufb6 NADH:ubiquinone oxidoreductase subunit B6 multiple interactions
decreases expression
ISO Acetylcysteine inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA]; coenzyme Q10 inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA] CTD PMID:19523936 NCBI chr 5:60,196,585...60,206,152
Ensembl chr 5:60,196,585...60,206,055
JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 affects localization
decreases expression
multiple interactions
increases activity
EXP
ISO
Galactosamine affects the localization of NFE2L2 protein
Galactosamine results in decreased expression of NFE2L2 protein
mangiferin affects the reaction [Galactosamine affects the localization of NFE2L2 protein]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of NFE2L2 protein]
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA]; Plant Extracts promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA]; Plant Extracts promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein]
Galactosamine results in increased activity of NFE2L2 protein
CTD PMID:22310181 PMID:28887131 PMID:30114225 PMID:30203046 PMID:30236599 NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [NFKB1 protein binds to NFKB1 protein]]; alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]]; Galactosamine results in increased activity of [NFKB1 protein binds to NFKB1 protein]; Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein] CTD PMID:17936189 NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions
decreases expression
EXP
ISO
Alprostadil inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]; Enzyme Inhibitors inhibits the reaction [Alprostadil inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]
[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA protein modified form; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA protein modified form]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein]
CTD PMID:15565661 PMID:20850421 PMID:22310181 PMID:28213090 PMID:30550845 NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions ISO [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NLRP3 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NLRP3 protein] CTD PMID:32453893 NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions
increases expression
ISO
EXP
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein]
[[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitrites; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NOS2 mRNA; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 mRNA]; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 promoter]; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; Enzyme Inhibitors inhibits the reaction [Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]]; Galactosamine promotes the reaction [Alprostadil results in increased expression of NOS2 protein]; Genistein inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; mangiferin inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NOS2 mRNA]
Galactosamine results in increased expression of NOS2 mRNA; Galactosamine results in increased expression of NOS2 promoter; Galactosamine results in increased expression of NOS2 protein
alpha-Tocopherol inhibits the reaction [Galactosamine results in increased expression of NOS2 mRNA]
CTD PMID:15189274 PMID:15565661 PMID:17936189 PMID:19796704 PMID:21401295 More... NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 decreases expression
multiple interactions
EXP
ISO
Galactosamine results in decreased expression of NQO1 protein
mangiferin inhibits the reaction [Galactosamine results in decreased expression of NQO1 protein]
8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NQO1 protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NQO1 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NQO1 protein; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NQO1 protein]
CTD PMID:22310181 PMID:28887131 PMID:35691465 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
JBrowse link
G Ocln occludin multiple interactions EXP [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN mRNA; [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN protein; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN mRNA]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN protein] CTD PMID:36414212 NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:33,391,303...33,430,411
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein; gentiopicroside inhibits the reaction [[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein] CTD PMID:20558151 NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of PIK3R1 protein]]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of PIK3R1 protein; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of PIK3R1 protein] CTD PMID:37934488 NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:34,612,946...34,626,347
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha increases expression
decreases expression
multiple interactions
increases activity
ISO Galactosamine results in increased expression of PPARA mRNA
Galactosamine results in decreased expression of PPARA mRNA
alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of PPARA mRNA]
Galactosamine results in increased activity of PPARA protein
[Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA mRNA; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA protein; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA mRNA; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA protein
CTD PMID:17936189 PMID:25689681 PMID:30203046 PMID:30236599 NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG protein; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG mRNA; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG protein; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG mRNA; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG protein; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG protein] CTD PMID:30236599 PMID:30550845 NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
JBrowse link
G Ppia peptidylprolyl isomerase A decreases expression EXP Galactosamine results in decreased expression of CYCA mRNA CTD PMID:22563491 NCBI chr14:85,491,223...85,496,884
Ensembl chr14:85,492,484...85,497,115
JBrowse link
G Ptgs1 prostaglandin-endoperoxide synthase 1 multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA] CTD PMID:22107987 NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
increases expression
ISO
EXP
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PTGS2 protein; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PTGS2 protein]
Galactosamine results in increased expression of PTGS2 protein
Genistein inhibits the reaction [Galactosamine results in increased expression of PTGS2 protein]
CTD PMID:22107987 PMID:25620059 PMID:32453893 NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
JBrowse link
G Ptn pleiotrophin increases expression EXP Galactosamine results in increased expression of PTN mRNA; Galactosamine results in increased expression of PTN protein CTD PMID:12057922 NCBI chr 4:66,260,764...66,342,614
Ensembl chr 4:66,260,764...66,342,482
JBrowse link
G Pttg1 PTTG1 regulator of sister chromatid separation, securin affects response to substance EXP PTTG1 mRNA affects the susceptibility to Galactosamine CTD PMID:19800905 NCBI chr10:28,394,940...28,406,410
Ensembl chr10:28,394,814...28,406,309
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
increases expression
ISO
EXP
[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA protein modified form; [Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein]
Galactosamine results in increased expression of RELA protein
mangiferin inhibits the reaction [Galactosamine results in increased expression of RELA protein]
alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]]; Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]
CTD PMID:17936189 PMID:20850421 PMID:22310181 PMID:30550845 NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
JBrowse link
G Sdc3 syndecan 3 increases expression EXP Galactosamine results in increased expression of SDC3 mRNA CTD PMID:12057922 NCBI chr 5:142,965,659...142,998,390
Ensembl chr 5:148,271,842...148,280,614
JBrowse link
G Serpine1 serpin family E member 1 increases expression EXP Galactosamine results in increased expression of SERPINE1 mRNA CTD PMID:11779202 NCBI chr12:25,237,977...25,248,356
Ensembl chr12:25,237,952...25,248,357
JBrowse link
G Sesn2 sestrin 2 multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of SESN2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of SESN2 protein CTD PMID:25637945 NCBI chr 5:149,986,304...150,005,255
Ensembl chr 5:149,986,317...150,005,255
JBrowse link
G Smad2 SMAD family member 2 multiple interactions
increases phosphorylation
EXP Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of SMAD2 protein] CTD PMID:27876602 NCBI chr18:72,124,792...72,193,345
Ensembl chr18:72,124,863...72,187,388
JBrowse link
G Smad3 SMAD family member 3 multiple interactions
increases phosphorylation
EXP Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of SMAD3 protein] CTD PMID:27876602 NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:73,024,760...73,132,324
JBrowse link
G Smad7 SMAD family member 7 multiple interactions
decreases expression
EXP Genistein inhibits the reaction [Galactosamine results in decreased expression of SMAD7 protein] CTD PMID:27876602 NCBI chr18:71,263,508...71,291,849
Ensembl chr18:71,263,508...71,291,849
JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of SOD1 mRNA CTD PMID:21401295 NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
JBrowse link
G Sord sorbitol dehydrogenase multiple interactions ISO [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of SORD protein; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of SORD protein] CTD PMID:30822415 NCBI chr 3:129,638,282...129,669,727
Ensembl chr 3:129,638,302...129,686,100
JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions ISO [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 protein]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEP gene mutant form results in increased susceptibility to Galactosamine]; SPP1 promotes the reaction [LEPR gene mutant form results in increased susceptibility to Galactosamine] CTD PMID:19913045 NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein] CTD PMID:28887131 NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359
JBrowse link
G Stat5b signal transducer and activator of transcription 5B decreases activity ISO Galactosamine results in decreased activity of STAT5B protein CTD PMID:30114225 NCBI chr10:86,205,148...86,276,178
Ensembl chr10:86,207,293...86,275,990
JBrowse link
G Tgfb1 transforming growth factor, beta 1 increases expression
multiple interactions
EXP Galactosamine results in increased expression of TGFB1 mRNA; Galactosamine results in increased expression of TGFB1 protein
Genistein inhibits the reaction [Galactosamine results in increased expression of TGFB1 mRNA]; Genistein inhibits the reaction [Galactosamine results in increased expression of TGFB1 protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TGFB1 protein]
CTD PMID:27836788 PMID:27876602 NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
JBrowse link
G Tjp1 tight junction protein 1 multiple interactions EXP [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 mRNA; [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 protein; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 mRNA]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 protein] CTD PMID:36414212 NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158
JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions ISO [Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TLR4 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TLR4 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TLR4 protein] CTD PMID:28125915 PMID:32453893 NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression
ISO
EXP
1-hydroxyalantolactone inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased expression of CCL2 mRNA]; 1-hydroxyalantolactone inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased expression of ICAM1 mRNA]; 1-hydroxyalantolactone inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased expression of VCAM1 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]]; 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA; [Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein; [TNF protein co-treated with Galactosamine] results in increased expression of CCL2 mRNA; [TNF protein co-treated with Galactosamine] results in increased expression of ICAM1 mRNA; [TNF protein co-treated with Galactosamine] results in increased expression of VCAM1 mRNA; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]]; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF protein]; Dithiothreitol inhibits the reaction [Nitric Oxide Donors inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; hydroquinone metabolite inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; nilotinib inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; Prednisolone inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]]
[ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of TNF protein; Alprostadil promotes the reaction [Galactosamine results in increased expression of TNF protein]; Genistein inhibits the reaction [Galactosamine results in increased expression of TNF protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TNF mRNA]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TNF protein]; mangiferin inhibits the reaction [Galactosamine results in increased expression of TNF mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of TNF protein]
[Galactosamine co-treated with TNF protein] results in increased activity of CASP3 protein; Galactosamine analog inhibits the reaction [TNF results in increased expression of ICAM1 protein]
Galactosamine results in increased expression of TNF mRNA; Galactosamine results in increased expression of TNF protein
CTD PMID:9388267 PMID:10221824 PMID:11779202 PMID:14512878 PMID:15135310 More... NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
JBrowse link
G Traf6 TNF receptor associated factor 6 multiple interactions ISO [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]] CTD PMID:28213090 NCBI chr 3:108,418,537...108,443,330
Ensembl chr 3:108,418,513...108,443,328
JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions ISO 1-hydroxyalantolactone inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased expression of VCAM1 mRNA]; [TNF protein co-treated with Galactosamine] results in increased expression of VCAM1 mRNA CTD PMID:25200604 NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions EXP 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of VEGFA mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of VEGFA mRNA CTD PMID:28844859 NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
JBrowse link
G Xdh xanthine dehydrogenase increases activity
multiple interactions
EXP Galactosamine results in increased activity of XDH protein
Vitamin U inhibits the reaction [Galactosamine results in increased activity of XDH protein]
CTD PMID:35673974 NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:27,282,057...27,344,350
JBrowse link
G Xiap X-linked inhibitor of apoptosis multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein; baicalein inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein]; Silymarin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein] CTD PMID:20850421 NCBI chr  X:125,756,107...125,803,979
Ensembl chr  X:125,737,971...125,803,978
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 20862
    role 20820
      biological role 20818
        biochemical role 20264
          metabolite 20245
            eukaryotic metabolite 19958
              animal metabolite 19803
                mammalian metabolite 19802
                  mouse metabolite 19428
                    D-galactosamine 111
                      2-amino-2-deoxy-D-galactopyranose + 111
                      D-galactosamine 1-phosphate + 0
                      D-galactosamine 6-phosphate 0
                      N-acetyl-D-galactosamine 6-phosphate 0
                      aldehydo-D-galactosamine 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 20862
    subatomic particle 20860
      composite particle 20860
        hadron 20860
          baryon 20860
            nucleon 20860
              atomic nucleus 20860
                atom 20860
                  main group element atom 20781
                    p-block element atom 20781
                      carbon group element atom 20715
                        carbon atom 20710
                          organic molecular entity 20710
                            heteroorganic entity 20219
                              organochalcogen compound 19904
                                organooxygen compound 19806
                                  carbohydrates and carbohydrate derivatives 15487
                                    carbohydrate 15487
                                      carbohydrate derivative 14459
                                        amino sugar 1493
                                          amino monosaccharide 1488
                                            hexosamine 1488
                                              galactosamine 111
                                                D-galactosamine 111
                                                  2-amino-2-deoxy-D-galactopyranose + 111
                                                  D-galactosamine 1-phosphate + 0
                                                  D-galactosamine 6-phosphate 0
                                                  N-acetyl-D-galactosamine 6-phosphate 0
                                                  aldehydo-D-galactosamine 0
paths to the root